Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:
- Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
- Helping pets live longer, healthier lives through advanced veterinary products.
- Improving food safety standards globally.
Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.
Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.
Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.
Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.
Elanco Foundation has partnered with the JBS Fund for the Amazon to support the RestaurAmazônia Project, aiming for sustainable farming in the Amazon. Over the next three years, Elanco will contribute $450,000 to Solidaridad Network. This initiative seeks to enhance cocoa and cattle production while preserving over 30,000 hectares of forest and reducing greenhouse gas emissions by 53%. Key targets include a 22% increase in livestock and a 40% increase in cocoa production. This partnership highlights Elanco's commitment to environmental conservation and improving rural livelihoods.
Elanco Animal Health has inked a definitive agreement to acquire Kindred Biosciences for $9.25 per share, valuing the deal at approximately $440 million. This acquisition aims to enhance Elanco's footprint in the pet health market, particularly in dermatology, with three potential blockbuster products and additional R&D programs in development. Elanco expects this combination to add $100 million to its 2025 innovation revenue target of $500-$600 million. The transaction is anticipated to close in Q3 2021, pending shareholder and regulatory approvals.
Elanco Animal Health (NYSE: ELAN) has signed a definitive agreement to acquire Kindred Biosciences (NASDAQ: KIN) for approximately $440 million, valuing KindredBio at $9.25 per share, a 52% premium. This acquisition aims to enhance Elanco's presence in the pet health market, particularly in dermatology, with three potential blockbuster products expected by 2025. Elanco anticipates that this deal will contribute an additional $100 million to its innovation revenue forecast of $500 million to $600 million by 2025. The acquisition is expected to close in Q3 2021, pending regulatory approvals.
TriRx Pharmaceutical Services announced an agreement to acquire two facilities from Elanco Animal Health, located in Shawnee, Kansas and Speke, United Kingdom. This acquisition includes physical assets and approximately 600 employees. The deal is set to enhance TriRx's manufacturing capacity and efficiency. A long-term supply agreement will maintain the production of existing Elanco products at these sites. The Shawnee facility is expected to close in the second half of 2021, while the Speke facility is anticipated to finalize by early 2022.
Elanco Animal Health (NYSE: ELAN) is optimizing its manufacturing footprint post-acquisition of Bayer Animal Health by selling its Shawnee, Kansas and Speke, UK sites to TriRx Pharmaceuticals. This includes a long-term supply agreement and the transfer of ~600 employees. The sale is expected to incur impairment charges of $245M to $305M in Q2 2021, impacting EPS guidance by $0.43 to $0.54. Elanco anticipates a reduction in annual capital expenditures by $25M to $30M while expecting gross margins to reach 60% by 2023. Additionally, operations in Brazil will be consolidated to enhance efficiency.
Elanco Animal Health has appointed Marcela A. Kirberger as the new general counsel and corporate secretary, effective June 22. Kirberger brings over 20 years of corporate legal experience, previously serving at Roche Diagnostics and other major firms. Her role will encompass all of Elanco’s legal functions. The company's CEO, Jeff Simmons, highlighted her extensive background in regulated and pharma sectors as a valuable asset. Kirberger is also an advocate for Indiana's life sciences industry and aims to make a positive impact on animal health.
Kindred Biosciences (NASDAQ: KIN) announced positive results from a pivotal study of KIND-030 for treating canine parvovirus. The trial showed a 100% survival rate in dogs treated with KIND-030 compared to 43% in the placebo group. This monoclonal antibody targets canine parvovirus, offering a single injection treatment that eliminates the need for costly hospitalization. The results indicate potential for both treatment and prevention of the disease, with submissions for regulatory approval expected soon. Parvovirus has a mortality rate up to 91% if untreated, making this a critical advancement.
Elanco Animal Health Incorporated (NYSE: ELAN) has announced its participation in two upcoming investor conferences in June. Jeff Simmons, the president and CEO, will hold a fireside chat at the Stifel 2021 Virtual Jaws & Paws Conference on June 3 at 2:30 p.m. ET, lasting approximately 25 minutes. He will also present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 9:40 a.m. ET for about 40 minutes. Both conferences will be virtual, with live webcasts accessible on Elanco's investor website.
Elanco Animal Health has launched ZoaShield™ in the U.S., a solution for poultry producers to manage coccidiosis effectively. This new product features a proven active ingredient, zoalene, which is vital for maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks. Elanco emphasizes that ZoaShield offers producers flexibility to suit various operational needs and seasons. Additionally, the company provides consultative support from experienced field experts, enhancing operational efficiency for poultry producers.
FAQ
What is the current stock price of Elanco Animal Health Incorporated (ELAN)?
What is the market cap of Elanco Animal Health Incorporated (ELAN)?
What is Elanco Animal Health's core mission?
In how many countries does Elanco operate?
What recent collaborations has Elanco engaged in?
What is the significance of Elanco's partnership with Athian?
What are some of Elanco's notable products?
How is Elanco addressing sustainability in animal farming?
What financial goals has Elanco set for 2024?
How does Elanco contribute to food safety?
What is Elanco's approach to innovation?
How does Elanco support the health and wellness of pets?
